Class summary at a glance.

Every drug in the Recombinant Human Deoxyribonuclease 1 class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $3.3Mcombined across class
Total Rx claims: 675180 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Dornase Alfa

Brand: Pulmozyme · 675 Part D claims (CY24) · 180 beneficiaries · First FDA approval: 1993-12-30

Brand-only (no generics) 326 plans require PA

Low NADAC$53.25

→

Avg plan cost$53.25

Part D spend $3.3M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.